Lisata Therapeutics, Inc.
Lisata Therapeutics, Inc. (Nasdaq: LSTA) is a clinical-stage pharmaceutical company developing therapies for solid tumors and other serious diseases. Its lead investigational product, certepetide, is designed to activate a tumor-specific transport pathway that helps co-administered anticancer drugs penetrate solid… From the company’s description.
In fiscal 2025, Lisata Therapeutics, Inc. reported revenue of $0.17M, down 83.0% from fiscal 2024, and a net loss of $16.59M. Operations used $15.95M in cash. Over the twelve months to Jun 30, 2026, revenue was $0.10M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Lisata Therapeutics, Inc. does
In the company’s own words
Lisata Therapeutics, Inc. (Nasdaq: LSTA) is a clinical-stage pharmaceutical company developing therapies for solid tumors and other serious diseases. Its lead investigational product, certepetide, is designed to activate a tumor-specific transport pathway that helps co-administered anticancer drugs penetrate solid tumors; it is also being studied for effects on the tumor microenvironment. Certepetide has been evaluated in clinical trials with chemotherapy, with and without immunotherapy, and is under study in several solid tumor types, including pancreatic, cholangiocarcinoma, colon, appendiceal and brain cancers. The company’s CendR Platform® supports development and potential collaborations involving chemotherapy, immunotherapy, targeted treatments and nucleic-acid-based therapies. Lisata’s business centers on research and development rather than reportable operating segments; its programs include company-sponsored and investigator-initiated trials, as well as technology collaboration and out-licensing opportunities. In fiscal 2025, Lisata remained focused on developing certepetide and its platform. The company was incorporated in 1980 and acquired Cend Therapeutics in 2022, bringing certepetide into its portfolio. Its website is www.lisata.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- BASKING RIDGE, NJ
- Fiscal year end
- December
- CIK
- 320017
- SIC
- 2834
Financial performance, year by year
Fiscal 2011–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Lisata Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Lisata Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Lisata Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Lisata Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Lisata Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”